152 related articles for article (PubMed ID: 26415921)
1. [Castleman's disease: Rapid desensitization for hypersensitivity reaction to rituximab].
Boin C; Lambert S; Thomann P; Aujoulat O; Kieffer P
Rev Med Interne; 2016 Jun; 37(6):433-6. PubMed ID: 26415921
[TBL] [Abstract][Full Text] [Related]
2. Desensitization to rituximab in a multidisciplinary setting.
Amorós-Reboredo P; Sánchez-López J; Bastida-Fernández C; do Pazo-Oubiña F; Borràs-Maixenchs N; Giné E; Valero A; Creus-Baró N
Int J Clin Pharm; 2015 Oct; 37(5):744-8. PubMed ID: 25999014
[TBL] [Abstract][Full Text] [Related]
3. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.
Wong JT; Long A
J Allergy Clin Immunol Pract; 2017; 5(6):1564-1571. PubMed ID: 29122155
[TBL] [Abstract][Full Text] [Related]
4. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
Brennan PJ; Rodriguez Bouza T; Hsu FI; Sloane DE; Castells MC
J Allergy Clin Immunol; 2009 Dec; 124(6):1259-66. PubMed ID: 19910036
[TBL] [Abstract][Full Text] [Related]
5. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
Shikdar S; Totton D; Turco T; Rachshtut M
Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
[TBL] [Abstract][Full Text] [Related]
6. Rituximab desensitization in three patients with severe rituximab allergy.
Öztürk E; Özyiğit LP; Öztürk AB; Akay MO; Çetiner M; Ferhanoğlu B
Curr Probl Cancer; 2017; 41(5):349-354. PubMed ID: 28860080
[TBL] [Abstract][Full Text] [Related]
7. Multicentric Castleman's disease masquerading as HIV-related lymphoma.
Dayyani F; Pantanowitz L; Sandridge TG; Sullivan RJ; Dezube BJ
Am J Med Sci; 2007 Oct; 334(4):317-9. PubMed ID: 18030193
[TBL] [Abstract][Full Text] [Related]
8. Multicentric Castleman's disease & HIV infection.
Cotter A; Lambert J; O'Gorman P
Ir Med J; 2009 Oct; 102(9):294-5. PubMed ID: 19902650
[TBL] [Abstract][Full Text] [Related]
9. Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience.
Görgülü B; Seval GC; Kendirlinan R; Toprak SK; Özcan M; Bavbek S
J Investig Allergol Clin Immunol; 2019; 29(6):468-470. PubMed ID: 31530515
[No Abstract] [Full Text] [Related]
10. [Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman's disease].
Ozawa T; Kosugi S; Kito M; Onishi M; Kida T; Nakata S; Take H; Katagiri S
Rinsho Ketsueki; 2014 Mar; 55(3):350-5. PubMed ID: 24681940
[TBL] [Abstract][Full Text] [Related]
11. Desensitisation overcomes rituximab- and tocilizumab-related immediate hypersensitivity in childhood.
Demir S; Soyer O; Bilginer Y; Sag E; Sahiner UM; Buyuktiryaki B; Sekerel BE; Ozen S
Clin Exp Rheumatol; 2020; 38(3):552-557. PubMed ID: 31820716
[TBL] [Abstract][Full Text] [Related]
12. Vinblastine, rituximab and HAART, treatment of an HIV -positive patient with multicentric Castleman's disease.
van Aalderen MC; Brinkman K; van den Berk GE; Terpstra WE
Neth J Med; 2010 Feb; 68(2):87-90. PubMed ID: 20167961
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.
Lebel E; Ben-Yehuda D; Bohbot E; Dranitzki Z; Shalit M; Tal Y
J Allergy Clin Immunol Pract; 2016; 4(5):1000-2. PubMed ID: 27329468
[No Abstract] [Full Text] [Related]
14. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.
Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M
Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536
[TBL] [Abstract][Full Text] [Related]
15. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab-CVP therapy.
Műzes G; Sipos F; Csomor J; Sréter L
APMIS; 2013 Jul; 121(7):668-74. PubMed ID: 23163599
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
17. Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.
Angenendt L; Kerkhoff A; Wiebe S; Mikesch JH; Rudat A; Wötzel F; Wenning C; Schliemann C; Kessler T; Schäfers M; Wardelmann E; Stelljes M; Berdel WE
Ann Hematol; 2015 Jul; 94(7):1241-3. PubMed ID: 25791243
[No Abstract] [Full Text] [Related]
18. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
Castells MC; Tennant NM; Sloane DE; Hsu FI; Barrett NA; Hong DI; Laidlaw TM; Legere HJ; Nallamshetty SN; Palis RI; Rao JJ; Berlin ST; Campos SM; Matulonis UA
J Allergy Clin Immunol; 2008 Sep; 122(3):574-80. PubMed ID: 18502492
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report.
Flejsierowicz M; Ahmed MS; Kotov P; Cheng YC
WMJ; 2008 Jul; 107(4):191-4. PubMed ID: 18702436
[TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity to biological agents-updated diagnosis, management, and treatment.
Galvão VR; Castells MC
J Allergy Clin Immunol Pract; 2015; 3(2):175-85; quiz 186. PubMed ID: 25754718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
